References
- Matzinger P. The danger model: a renewed sense of self. Science296, 301–305 (2002).
- Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine24(Suppl. 2), S2–26–29 (2006).
- Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol.82, 488–496 (2004).
- Silva DG, Cooper PD, Petrovsky N. Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol. Cell Biol.82, 611–616 (2004).
- Romero Mendez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine25, 825–833 (2007).
- Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev.32, 155–172 (1998).
- Goto N, Kato H, Maeyama J, Shibano M, Saito T, Yamaguchi J, Yoshihara S. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine15, 1364–1371 (1997).
- Hall JG. Studies on the adjuvant action of beryllium. IV. The preparation of beryllium containing macromolecules that induce immunoblast responses in vivo. Immunology64, 345–351 (1988).
- Byars N, Allison A. Immunologic adjuvants: general properties, advantages and limitations. In: Laboratory Methods in Immunology. Zola H (Ed.). CRC Press, FL, USA 39–51 (1990).
- Bangham AD, Horne RW, Glauert AM, Dingle JT, Lucy JA. Action of saponin on biological cell membranes. Nature196, 952–955 (1962).
- Kensil CR. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst.13, 1–55 (1996).
- Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol.146, 431–437 (1991).
- Wu JY, Gardner BH, Murphy CI et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol.148, 1519–1525 (1992).
- Freund J. The mode of action of immunologic adjuvants. Bibl. Tuberc. 130–148 (1956).
- De Becker G, Moulin V, Pajak B et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12, 807–815 (2000).
- Garcon N, Heppner DG, Cohen J. Development of RTS,S/AS02, a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines2, 231–238 (2003).
- Levie K, Gjorup I, Skinhoj P, Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand. J. Infect. Dis.34, 610–614 (2002).
- Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon γ as a marker for adjuvants that enhance protective immunity. Res. Immunol.143, 483–488; discussion 573–484 (1992).
- Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol.6, 495–524 (1995).
- Hartmann G, Weeratna RD, Ballas ZK et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol.164, 1617–1624 (2000).
- Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, interferon γ. Proc. Natl Acad. Sci. USA93, 2879–2883 (1996).
- Krug A, Rothenfusser S, Selinger S et al. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol.170, 3468–3477 (2003).
- Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine17, 19–25 (1999).
- Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG (7909), a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. (1997)27, 460–471 (2004).
- Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol.28, 279–284 (1991).
- Waters RV, Terrell TG, Jones GH. Uveitis induction in the rabbit by muramyl dipeptides. Infect. Immun.51, 816–825 (1986).
- Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants – a balance between toxicity and adjuvanticity. Vaccine11, 293–306 (1993).
- Goto N, Kato H, Maeyama J, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine11, 914–918 (1993).
- Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine21, 4234–4237 (2003).
- Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol.162, 5536–5546 (1999).
- Ronnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine13, 1375–1382 (1995).
- Cooper PD. Vaccine adjuvants based on γ inulin. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum Press, NY, USA 559–580 (1995).
- Cooper PD, McComb C, Steele EJ. The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine 9, 408–415 (1991).
- Cooper PD, Steele EJ. Algammulin, a new vaccine adjuvant comprising γ inulin particles containing alum: preparation and in vitro properties. Vaccine9, 351–357 (1991).
- Cooper PD, Steele EJ. The adjuvanticity of γ inulin. Immunol. Cell Biol.66 (Pt 5–6), 345–352 (1988).
- Frazer I, Tindle RW, Fernando G et al. Safety and immunogenicity of HPV16 E7/Algammulin. In: Vaccines for Human Papillomavirus Infection and Anogenital Disease. Tindle RW (Ed.). RG Landes, NY, USA 91–104 (1999).